Variation in access and prescription of vedolizumab and ustekinumab in paediatric patients with inflammatory bowel disease: a UK-wide study

Conclusions There is widespread use of vedolizumab and ustekinumab across the UK, although practice is highly variable. Access to therapy appeared to differ substantially. There is a growing disparity between international guidelines and real-world practice. Establishing early and effective therapy in all patients remains a priority.

http://adc.bmj.com/cgi/content/short/108/12/994?rss=1

Source: Archives of Disease in Childhood - November 17, 2023 Category: Pediatrics Authors: Auth, M. K.-H., Ashton, J. J., Jones, K. D. J., Rodrigues, A., Thangarajah, D., Devadason, D., Lee, G., Ayaz, M., Lee, H. M., Kammermeier, J., BSPGHAN IBD Biologics Survey Contributors, Lee, Swann, Garrick, Torrente, Deb, Doble, Paul, Coelho, Zamvar, Naru Tags: Original research Source Type: research